
Clearside Biomedical Inc
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $0.9474
- Today's High:
- $0.9839
- Open Price:
- $0.9623
- 52W Low:
- $0.9
- 52W High:
- $2.54
- Prev. Close:
- $0.96
- Volume:
- 87259
Company Statistics
- Market Cap.:
- $58.56 million
- Book Value:
- 0.175
- Revenue TTM:
- $1.33 million
- Operating Margin TTM:
- -2281.61%
- Gross Profit TTM:
- $1.12 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -40.17%
- Return on Equity TTM:
- -135.64%
Company Profile
Clearside Biomedical Inc had its IPO on 2016-06-02 under the ticker symbol CLSD.
The company operates in the Healthcare sector and Biotechnology industry. Clearside Biomedical Inc has a staff strength of 36 employees.
Stock update
Shares of Clearside Biomedical Inc opened at $0.96 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $0.95 - $0.98, and closed at $0.96.
This is a -0.31% slip from the previous day's closing price.
A total volume of 87,259 shares were traded at the close of the day’s session.
In the last one week, shares of Clearside Biomedical Inc have slipped by -5.25%.
Clearside Biomedical Inc's Key Ratios
Clearside Biomedical Inc has a market cap of $58.56 million, indicating a price to book ratio of 3.927 and a price to sales ratio of 2.6392.
In the last 12-months Clearside Biomedical Inc’s revenue was $1.33 million with a gross profit of $1.12 million and an EBITDA of $-30132000. The EBITDA ratio measures Clearside Biomedical Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Clearside Biomedical Inc’s operating margin was -2281.61% while its return on assets stood at -40.17% with a return of equity of -135.64%.
In Q4, Clearside Biomedical Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98.7%.
Clearside Biomedical Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.5 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Clearside Biomedical Inc’s profitability.
Clearside Biomedical Inc stock is trading at a EV to sales ratio of 0.7441 and a EV to EBITDA ratio of -4.8278. Its price to sales ratio in the trailing 12-months stood at 2.6392.
Clearside Biomedical Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $51.30 million
- Total Liabilities
- $5.78 million
- Operating Cash Flow
- $-91000.00
- Capital Expenditure
- $154754
- Dividend Payout Ratio
- 0%
Clearside Biomedical Inc ended 2023 with $51.30 million in total assets and $0 in total liabilities. Its intangible assets were valued at $51.30 million while shareholder equity stood at $10.61 million.
Clearside Biomedical Inc ended 2023 with $0 in deferred long-term liabilities, $5.78 million in other current liabilities, 61000.00 in common stock, $-288438000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.26 million and cash and short-term investments were $48.26 million. The company’s total short-term debt was $349,000 while long-term debt stood at $0.
Clearside Biomedical Inc’s total current assets stands at $49.40 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.05 million and inventory worth $0.
In 2023, Clearside Biomedical Inc's operating cash flow was $-91000.00 while its capital expenditure stood at $154754.
Comparatively, Clearside Biomedical Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $0.96
- 52-Week High
- $2.54
- 52-Week Low
- $0.9
- Analyst Target Price
- $5.8
Clearside Biomedical Inc stock is currently trading at $0.96 per share. It touched a 52-week high of $2.54 and a 52-week low of $2.54. Analysts tracking the stock have a 12-month average target price of $5.8.
Its 50-day moving average was $1.24 and 200-day moving average was $1.33 The short ratio stood at 2.17 indicating a short percent outstanding of 0%.
Around 745.2% of the company’s stock are held by insiders while 2815.8% are held by institutions.
Frequently Asked Questions About Clearside Biomedical Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.